{"entity":{"id":"nct07284433","kind":"trial","name":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","aka":[],"tldr":"A phase 1/2 trial of Allo-QuadCAR01-T in diffuse large B-cell lymphoma and non-Hodgkin lymphoma, run by AvenCell Therapeutics, Inc., now recruiting.","summary":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies is a phase 1/2 interventional study registered as NCT07284433 by AvenCell Therapeutics, Inc., with 178 participants planned, started 2026-01-06 and due to reach its primary completion in 2029-04-27. Interventions recorded: Allo-QuadCAR01-T.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07284433","url":"https://clinicaltrials.gov/study/NCT07284433"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07284433","phase":"1/2","setting":"A Single-arm, Multicenter, Open-label, Phase I/II Trial of Allo-QuadCAR01-T, an Allogeneic CAR-T-cell Therapy Targeting CD19 and CD20, for the Treatment of Relapsed or Refractory B-cell Malignancies","sponsor":"AvenCell Therapeutics, Inc.","enrolled":178,"outcomes":[]},"route":"/trials/nct07284433/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}